BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tateyama M, Naoe H, Tanaka M, Tanaka K, Narahara S, Tokunaga T, Kawasaki T, Yoshimaru Y, Nagaoka K, Watanabe T, Setoyama H, Sasaki Y, Tanaka Y. Loss of skeletal muscle mass affects the incidence of minimal hepatic encephalopathy: a case control study. BMC Gastroenterol 2020;20:371. [PMID: 33167879 DOI: 10.1186/s12876-020-01501-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Kim Y. Emerging Treatment Options for Sarcopenia in Chronic Liver Disease. Life (Basel) 2021;11:250. [PMID: 33803020 DOI: 10.3390/life11030250] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
2 Lattanzi B, Bruni A, Di Cola S, Molfino A, De Santis A, Muscaritoli M, Merli M. The Effects of 12-Week Beta-Hydroxy-Beta-Methylbutyrate Supplementation in Patients with Liver Cirrhosis: Results from a Randomized Controlled Single-Blind Pilot Study. Nutrients 2021;13:2296. [PMID: 34371806 DOI: 10.3390/nu13072296] [Reference Citation Analysis]
3 Lee CM, Kang BK, Kim M. Radiologic Definition of Sarcopenia in Chronic Liver Disease. Life (Basel) 2021;11:86. [PMID: 33504046 DOI: 10.3390/life11020086] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Lee CM, Kang BK, Kim M. Radiologic Definition of Sarcopenia in Chronic Liver Disease.Life (Basel). 2021;11. [PMID: 33504046 DOI: 10.3390/life11020086.] [Reference Citation Analysis]